Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Arbutus Biopharma Corp changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Of which not filed for Q2 2025 | Q2 2025 | Change |
|---|---|---|---|---|
| Holders | 168 | 1 | 163 | −4 |
| Shares | 111.8M | 284 | 118.1M | +6.33M (+5.7%) |
| Value | $390.1M | $991 | $365.0M | −$25.1M (−6.4%) |
1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Arbutus Biopharma Corp at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Schroder Investment Management Group | 121,313 | $374.9K | 0.00% |
| Nomura Holdings Inc | 96,280 | $297.5K | 0.00% |
| Exome Asset Management LLC | 75,484 | $233.2K | 0.19% |
| D. E. Shaw & Co., Inc. | 40,700 | $125.8K | 0.00% |
| Assenagon Asset Management S.A. | 39,610 | $122.4K | 0.00% |
| Man Group plc | 38,997 | $120.5K | 0.00% |
| Prelude Capital Management, LLC | 25,318 | $78.2K | 0.01% |
| Sherbrooke Park Advisers LLC | 21,634 | $66.8K | 0.03% |
| Los Angeles Capital Management LLC | 19,655 | $60.7K | 0.00% |
| Axq Capital, LP | 18,545 | $57.3K | 0.02% |
| Two Sigma Securities, LLC | 16,785 | $51.9K | 0.01% |
| Oxford Asset Management LLP | 12,143 | $37.5K | 0.01% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,756 | $5.00K | 0.00% |
| MAI Capital Management | 601 | $1.86K | 0.00% |
Sold out (18)
Institutions that held Arbutus Biopharma Corp at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| StemPoint Capital LP | 467,882 | $1.63M |
| Susquehanna Fundamental Investments, LLC | 115,295 | $402.4K |
| Corebridge Financial, Inc. | 71,572 | $249.8K |
| Rockefeller Capital Management L.P. | 63,000 | $219.9K |
| Balyasny Asset Management LLC | 18,916 | $66.0K |
| HSBC Holdings PLC | 16,883 | $58.7K |
| Jain Global LLC | 13,200 | $46.1K |
| SIH Partners, LLLP | 12,318 | $43.0K |
| State of Wisconsin Investment Board | 12,294 | $42.9K |
| Dynamic Wealth Strategies, LLC | 6,300 | $22.0K |
| Boston Private Wealth LLC | 1,719 | $6.00K |
| Quadrant Capital Group LLC | 878 | $3.06K |
| Picton Mahoney Asset Management | 228 | $1.00K |
| Coldstream Capital Management Inc | 284 | $992 |
| UMA Financial Services, Inc. | 283 | $988 |
| Farther Finance Advisors, LLC | 266 | $926 |
| Loring Wolcott & Coolidge Fiduciary Advisors LLP | 200 | $648 |
| GAMMA Investing LLC | 127 | $443 |
Not filed for Q2 2025 yet (1)
Institutions that held Arbutus Biopharma Corp at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Lindbrook Capital, LLC | 284 | $991 |